Creative Biolabs recently rolled out a three-dimensional upgrade designed to make antibodies safer, more potent, and easier to develop. SHIRLEY, NY, UNITED STATES, June 18, 2025 /EINPresswire.com/ -- ...

Charnelda G. Ruffin, Pharm.D., is Clinical Pharmacy Specialist, Kaiser Permanente, Atlanta, GA; at the time of writing she was Clinical Information Pharmacist, ACS State Healthcare, Atlanta ...

2006. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 18:1759-69.

Arialys Therapeutics' precision medicine has shown preclinical potential to address the underlying cause of anti-NMDA ...

The FDA approves INCY's Monjuvi in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, its second approved indication.

Discover why BeOne Medicines (BEIGF) is a strong Buy with growth driven by Brukinsa, Tevimbra, and a promising oncology ...

The webcast of the fireside chat may be accessed by visiting the Events page of the Company’s website at www.promisneurosciences.com, and will be available for at least 30 days following the event.

The FDA has granted Fast Track designation to nadunolimab to treat patients with previously untreated metastatic pancreatic ductal adenocarcinoma.

Among children and adolescents with episodic migraine, fremanezumab significantly reduced monthly migraine days.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in ...

WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company ...